Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 6/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 6/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 6/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 6/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | APEX1 | P27695 | 2/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11730865 | 0.98 | CHRM2 (0.96) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Oxotremorine SCHEMBL10532590 | 0.98 | CHRM2 (0.96) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL11726410 | 0.98 | CHRM2 (0.96) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL11724836 | 0.98 | CHRM2 (0.96) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL11725498 | 0.98 | CHRM2 (0.96) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL11726121 | 0.96 | CHRM2 (0.93) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL31263727 | 0.96 | CHRM2 (0.93) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Oxotremorine SCHEMBL1320883 | 0.95 | CHRM2 (0.90) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL11721410 | 0.94 | CHRM2 (0.89) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL11727343 | 0.94 | CHRM2 (0.89) | CHRM2CHRM5CHRM1CHRM3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2979 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590297-B2 | Differentiation method | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2026-03-31 | — | — | US | claimed |
| US-20250186415-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2025-06-12 | — | — | US | claimed |
| US-20250127760-A1 | COMPOSITION AND USE THEREOF IN PREPARATION OF MEDICAMENT FOR TREATING PRESBYOPIA | SHENYANG XINGQI PHARMACEUTICAL CO., LTD. (CN) | 2025-04-24 | — | — | US | claimed |
| US-12262990-B2 | Methods and materials for prolonged sweat stimulation | UNIVERSITY OF CINCINNATI (US) | 2025-04-01 | — | — | US | claimed |
| US-20250049761-A1 | COMPOSITIONS AND METHODS FOR TREATING PRESBYOPIA, MILD HYPEROPIA, AND IRREGULAR ASTIGMATISM | ALLERGAN, INC. | 2025-02-13 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| EP-4489858-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | Harrow IP, LLC (US) | 2025-01-15 | — | — | EP | claimed |
| US-12161629-B2 | Methods and compositions for treatment of glaucoma and related conditions | OPUS GENETICS, INC. (US) | 2024-12-10 | — | — | US | claimed |
| EP-4458356-A1 | COMPOSITION AND USE THEREOF IN PREPARATION OF MEDICAMENT FOR TREATING PRESBYOPIA | Shenyang Xingqi Pharmaceutical Co., Ltd. (CN) | 2024-11-06 | — | — | EP | claimed |
| US-20240325324-A1 | COMPOSITIONS AND METHODS FOR TREATING DRY EYE | Genetic Disease Investigators, LLC | 2024-10-03 | — | — | US | claimed |
| WO-1996013257-A1 | USE OF RECEPTOR POTENTIATORS | MERCK & CO., INC. (US) | 1996-05-09 | — | — | WO | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| US-5364629-A | Fatty acid ester of C1-2 mono- or diol | PHARMETRIX CORP. (US) | 1994-11-15 | — | — | US | claimed |
| EP-0523150-A4 | DEVICE AND METHOD FOR ENHANCED ADMINISTRATION OF PHYSOSTIGMINE | — | 1993-09-29 | — | — | EP | claimed |
| EP-0523150-A1 | DEVICE AND METHOD FOR ENHANCED ADMINISTRATION OF PHYSOSTIGMINE | PHARMETRIX CORPORATION (US) | 1993-01-20 | — | — | EP | claimed |
| WO-1991015176-A1 | DEVICE AND METHOD FOR ENHANCED ADMINISTRATION OF PHYSOSTIGMINE | PHARMETRIX CORPORATION (US) | 1991-10-17 | — | — | WO | claimed |
| US-5010056-A | Growth disorders | PIERREL SPA (IT) | 1991-04-23 | — | — | US | claimed |
| EP-0301392-A1 | Pharmaceutical composition for intranasal administration comprising GH - Releasing hormone, a cholinergic agonist and in case a bile salt | Pierrel S.p.A. (IT) | 1989-02-01 | — | — | EP | claimed |
| US-4788063-A | FATTY ACID, CHOLINERGIC OR ANTICHOLINERGIC AGENT | STATE OF ISRAEL, REPRESENTED BY PRIME MINISTER'S OFFICE ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1988-11-29 | — | — | US | claimed |
| US-4665069-A | PARASYMPATHOMIMETIC AGENT | ROSENBERG BARNETT | 1987-05-12 | — | — | US | claimed |